Method for separating and purifying temsirolimus
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- YANGTZE RIVER PHARM GRP SICHUAN HAIRONG PHARM CO LTD
- Publication Date
- 2019-06-07
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of separation and purification of generic drugs, in particular to a method for separation and purification of temsirolimus. Background technique
[0002] Temsirolimus (Temsirolimus) (Temsirolimus) (Temsirolimus) (Temsirolimus) (Temsirolimus) is an intravenous injection of mTOR inhibitors, approved for the treatment of advanced renal cell carcinoma, is a derivative and prodrug of sirolimus. Tesirolimus uses rapamycin (sirolimus) as a raw material, through esterification, deprotection and other synthetic processes to generate temsirolimus finished product with low purity and high isomer content. Most of the current research reports are the separation and purification methods of rapamycin (sirolimus) (CN104844620A, CN107619413A, etc.). According to reaxys search, there are few reports on the isolation and purification of temsirolimus. Zheng Congshen et al. announced a refinement study of temsirolimus in the "13th Natio...